Biocon Limited — JV/Acquisition, 05-01-2026: Acquisition

Biocon Limited has significantly boosted its stake in subsidiary Biocon Biologics (BBL) to approximately 94% on a fully diluted basis, consolidating control over its key biologics business. The acquisition involved two parts: 26.19 crore BBL shares were acquired through a preferential allotment of 17.13 crore Biocon shares to various investors at Rs. 405.78 each, valuing this segment at around Rs. 6,953.50 Cr. Additionally, Biocon acquired 7.18 crore BBL shares from Mylan for USD 200 million cash. This strategic move strengthens Biocon's core biologics portfolio.